SEARCH
Subscribe
Track all markets on TradingView

FSD Pharma Canntab Partnership Has HUGE Upside

Published:

Reading time: 3 min.

In this market news, FSD Pharma (CSE:HUGE), one of the Canadian marijuana stocks, said it has signed a profit-sharing agreement with Canntab Therapeutics Limited (CSE:PILL)

SmallCapPower | September 19, 2018: FSD Pharma (CSE:HUGE), a licensed producer of cannabis, Tuesday announced that it has signed a definitive collaboration and profit-sharing agreement with Canntab Therapeutics Limited (CSE:PILL), a company focused on cannabis oral dosage formulations. The deal is a major positive for both companies as cannabis-based tablets offer a significant opportunity since doctors hesitate to prescribe smoked cannabis as a solution to patients’ health concerns. Following the announcement, shares of Canadian cannabis stocks FSD Pharma and Canntab rose 7% and 22%, respectively.

For Our Complete Coverage Of Canadian Marijuana Stocks Click Here    

Watch: Cannex Capital Holdings (CSE:CNNX) Wants to Emerge as a Multi-State U.S. Player, Says CEO 

As per the agreement, FSD Pharma will provide Canntab with space at its Cobourg facility, where Canntab will install, at its own expense, a GMP facility to produce a suite of novel cannabis oral dose delivery platforms, including gel capsules and tablets, and other types of cannabis-based products, including sleep aids and pain relievers. FSD Pharma will also assist Canntab to obtain a license to process and sell cannabis products.

Win Big With Our Small Cap Picks

 

In return, Canntab will grant certain royalty and profit-sharing rights. Canntab provides FSD with 50% of the profits from retail sales of Canntab Products through channels established by FSD Pharma, while FSD will be entitled to retain 50% of the profits on FSD Pharma’s sales of the Canntab products. Additionally, a royalty of 3.5% of Canntab’s sale price for all products manufactured and sold at Canntab premises will be paid by Canntab to FSD Pharma.

FSD Pharma currently trades at a market cap of $954 million on the CSE with a price-to-book multiple of 18.0x.

Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.

To read our full disclosure, please click on the button below:

The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
jsteppke
jsteppke

Related articles

Recent articles

© SmallCapPower 2024